Emergent BioSolutions Stock Jumps 13%

Shares of Emergent BioSolutions Inc. (EBS) are gaining over 13% on Thursday morning.

EBS is currently trading at $32.16, up $3.82 or 13.48%, on the NYSE. The stock opened its trading at $32.59 after closing Wednesday's trading at $28.34. The stock has traded between $27.61 and $68.03 in the past 52-week period.

Emergent BioSolutions, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States.

On Monday, Emergent BioSolutions announced a deal with Chimerix, Inc. (CMRX), to acquire Chimerix's exclusive worldwide rights to Tembexa (brincidofovir), the first antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT